Understanding Your Treatment Choices After a Blood Cancer Diagnosis

The diagnosis of chronic lymphocytic leukemia (CLL) can be overwhelming, and may raise many questions about what lies ahead. Treatment approaches for blood cancers have evolved over the last several years. With ongoing research, treatment has expanded beyond traditional chemotherapy to include targeted therapies that act on specific biological pathways involved in CLL, targeted treatment aimed at disrupting cancer cells’ ability to survive and multiply.

These modern options can be confusing for patients and their families if they are not familiar with the way various medications work. This guide discusses how the use of Bruton’s tyrosine kinase (BTK) inhibitors has changed over time in the treatment of CLL, to give you some context for conversations with your health care team.

The Move Towards Targeted Therapy

In the past, most blood cancers were treated with chemotherapy. These treatments were effective in destroying rapidly dividing cells but they also affected healthy cells as well, causing a lot of side effects. Targeted therapies have become an important component of modern hematology practice. These drugs target proteins or markers on the surface of leukemia cells and turn off the signals that promote the growth of the leukemia.

One of the key components of this strategy is the use of BTK inhibitors. These molecules inhibit Bruton’s tyrosine kinase (BTK), a protein involved in B-cell receptor signaling that supports the survival and proliferation of malignant B cells. BTK inhibitors are designed to target the BTK pathway involved in B-cell signaling.

A Comparison of BTK Inhibitor Options

Clinicians are increasingly seeking head-to-head clinical trial data to compare efficacy and safety in order to better inform their treatment choices as protocols are optimized. When comparing drugs such as zanubrutinib vs ibrutinib, the primary factors to consider are disease control and side effect profiles.

Progression-free Survival (%) and Response Rate (%)

Randomized Phase 3 clinical trials have provided comparative evidence regarding BTK inhibitors in relapsed or refractory CLL, and have offered some insight into their performance in the relapsed or refractory context. When comparing the effects of different treatments, researchers evaluate progression-free survival (PFS), which measures the length of time a patient lives without disease progression, called progression-free survival (PFS), and the proportion of patients with measurable improvement in disease activity. Clinical trials have evaluated differences in progression-free survival and other outcomes among BTK inhibitors.

Safety and Tolerability

In addition to efficacy, the tolerance of a treatment regimen is important. CLL is typically a chronic condition and the side effects of a treatment can have a lot to do with how the patient lives their daily lives. Studies comparing the different BTK inhibitors have revealed differences in their studies have evaluated differences in off-target kinase inhibition, which may contribute to variations in safety profiles among BTK inhibitors. 

One of the main considerations in next generation drug design is minimising off target inhibition. Drug development efforts have investigated approaches to improve selectivity and characterize safety profiles that could cause these patients to discontinue treatment; these side effects include cardiac side effects like irregularities, and treatment-related fatigue.

A Personalized Approach to Managing CLL

There is no such thing as a typical patient. One person’s treatment program may not be the best for another person. Your healthcare team will look at a number of factors to find the route forward:

• Genetic Markers: New testing that identifies specific mutations in the TP53 gene or 17p deletion can help determine how the cancer will likely respond to some drugs.
• Overall Health and Comorbidities: Your doctor will examine your past health, especially around heart health or prior allergic responses to medications to pick a treatment that poses as little risk as possible.
• Patient Goals: If you have other work, family or personal goals that you would like to consider, it is important to share these with your doctor and they will be part of the decision-making process.

There is still a place to watch and wait (active surveillance) for many CLL patients in early disease. In some patients, however, treatment may not be needed immediately if their condition is stable and they have no symptoms. This ongoing surveillance enables your health care team to only make a treatment decision when it’s warranted by your disease, thereby avoiding unnecessary complications.

Frequently Asked Questions (FAQs)

1. The main goal of a BTK inhibitor in the treatment of CLL is? 

BTK inhibitors target Bruton’s tyrosine kinase (BTK), a protein involved in B-cell signaling. The drug blocks the pathway through which the abnormal B-cells are able to grow.

2. What are the differences in the selection of BTK inhibitors by doctors? 

Which is chosen depends on a range of clinical related parameters such as the patient’s genetic profile (e.g. TP53 mutation), cardiac history, patient lifestyle and personal choice. Head-to-head clinical trials are conducted to decide which drug has the best efficacy/safety profile in a particular patient population.

3. Do you still recommend watching and waiting for CLL? 

Yes. In many people with early-stage (ASL) CLL, no treatment is needed at this time, and treatment should be considered the watch and wait (active surveillance). It requires frequent blood and physical examinations to keep track of the disease and only treats it when needed clinically.

4. What should I discuss with my doctor before starting a new medication? 

Questions to ask include the purpose of the treatment, the side effects to anticipate, what dosage and how the medicine is supposed to be taken and if any lifestyle changes are required. Also, inquire about the effect of your own genetic makeup on what medicine you may be prescribed.

Conclusion

Treatment options for CLL have evolved over time as understanding of the disease has expanded, and reflecting a better understanding of disease biology. The language may be complicated but the goal is simple: The goal of treatment is disease management while considering patient quality of life. Whether you are talking about frontline choices or considering a switch in therapy, it is important to know some of the differences between the therapies available, so you can work closely with your healthcare team. 

Be sure to ask your hematologist or oncologist about options that are best for your diagnosis. Maintaining regular communication with your healthcare providers allows treatment to be responsive to the most up-to-date knowledge and your personal requirements.